

Mattia Boeri

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1008106/mattia-boeri-publications-by-citations.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

37 papers	2,186 citations	21 h-index	42 g-index
42 ext. papers	2,679 ext. citations	4.8 avg, IF	4.7 L-index

#	Paper	IF	Citations
37	MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 3713-8	11.5	571
36	Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. <i>Journal of Clinical Oncology</i> , 2014 , 32, 768-73	2.2	290
35	Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade. <i>Clinical Cancer Research</i> , 2019 , 25, 989-998	12.9	213
34	Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy. <i>Annals of Oncology</i> , 2019 , 30, 1162-1169	10.3	152
33	Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 343-357	8.9	142
32	Role of microRNAs in lung cancer: microRNA signatures in cancer prognosis. <i>Cancer Journal (Sudbury, Mass.)</i> , 2012 , 18, 268-74	2.2	78
31	Unexpected detection of SARS-CoV-2 antibodies in the prepandemic period in Italy. <i>Tumori</i> , 2021 , 107, 446-451	1.7	74
30	Mir-660 is downregulated in lung cancer patients and its replacement inhibits lung tumorigenesis by targeting MDM2-p53 interaction. <i>Cell Death and Disease</i> , 2014 , 5, e1564	9.8	64
29	Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening. <i>Oncotarget</i> , 2015 , 6, 32868-77	3.3	57
28	YAP1 acts as oncogenic target of 11q22 amplification in multiple cancer subtypes. <i>Oncotarget</i> , 2014 , 5, 2608-21	3.3	52
27	Assessment of circulating microRNAs in plasma of lung cancer patients. <i>Molecules</i> , 2014 , 19, 3038-54	4.8	50
26	Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study. <i>Clinical Cancer Research</i> , 2019 , 25, 2166-2173	12.9	47
25	Exo-miRNAs as a New Tool for Liquid Biopsy in Lung Cancer. <i>Cancers</i> , 2019 , 11,	6.6	41
24	Prognostic determinants in epithelioid sarcoma. <i>European Journal of Cancer</i> , 2011 , 47, 287-95	7.5	40
23	Potential biomarkers for lung cancer screening. <i>Translational Lung Cancer Research</i> , 2014 , 3, 139-48	4.4	38
22	Circulating mir-320a promotes immunosuppressive macrophages M2 phenotype associated with lung cancer risk. <i>International Journal of Cancer</i> , 2019 , 144, 2746-2761	7.5	37
21	Therapeutic use of microRNAs in lung cancer. <i>BioMed Research International</i> , 2014 , 2014, 756975	3	34

20	Establishment of patient derived xenografts as functional testing of lung cancer aggressiveness. <i>Scientific Reports</i> , 2017 , 7, 6689	4.9	30
19	Stopping Smoking Reduces Mortality in Low-Dose Computed Tomography Screening Participants. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 693-699	8.9	28
18	Recent advances of microRNA-based molecular diagnostics to reduce false-positive lung cancer imaging. <i>Expert Review of Molecular Diagnostics</i> , 2015 , 15, 801-13	3.8	27
17	MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier (MSC) for Lung Cancer Screening. <i>Journal of Visualized Experiments</i> , 2017 ,	1.6	21
16	Baseline and postoperative C-reactive protein levels predict mortality in operable lung cancer. <i>European Journal of Cancer</i> , 2017 , 79, 90-97	7.5	20
15	Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial. <i>Lung Cancer</i> , 2019 , 132, 17-23	5.9	11
14	DRAGO (KIAA0247), a new DNA damage-responsive, p53-inducible gene that cooperates with p53 as oncosuppressor. [Corrected]. <i>Journal of the National Cancer Institute</i> , 2014 , 106, dju053	9.7	11
13	Mutational Profile from Targeted NGS Predicts Survival in LDCT Screening-Detected Lung Cancers. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 922-931	8.9	10
12	Baseline and Postoperative C-reactive Protein Levels Predict Long-Term Survival After Lung Metastasectomy. <i>Annals of Surgical Oncology</i> , 2019 , 26, 869-875	3.1	9
11	Age-Related Alterations in Immune Contexture Are Associated with Aggressiveness in Rhabdomyosarcoma. <i>Cancers</i> , 2019 , 11,	6.6	6
10	Inflammatory status and lung function predict mortality in lung cancer screening participants. <i>European Journal of Cancer Prevention</i> , 2018 , 27, 289-295	2	6
9	Gene Signatures Stratify Computed Tomography Screening Detected Lung Cancer in High-Risk Populations. <i>EBioMedicine</i> , 2015 , 2, 831-40	8.8	5
8	MicroRNA Profile of Lung Tumor Tissues Is Associated with a High Risk Plasma miRNA Signature. <i>Microarrays (Basel, Switzerland)</i> , 2016 , 5,		5
7	LKB1 Down-Modulation by miR-17 Identifies Patients With NSCLC Having Worse Prognosis Eligible for Energy-Stress-Based Treatments. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 1298-1311	8.9	5
6	Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with Immunotherapy.. <i>Cancers</i> , 2022 , 14,	6.6	4
5	Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system. <i>Translational Lung Cancer Research</i> , 2020 , 9, 617-628	4.4	3
4	Improved Prognostic Prediction in Never-Smoker Lung Cancer Patients by Integration of a Systemic Inflammation Marker with Tumor Immune Contexture Analysis. <i>Cancers</i> , 2020 , 12,	6.6	1
3	Biomolecular and clinical practice in malignant pleural mesothelioma and lung cancer: what thoracic surgeons should know. <i>European Journal of Cardio-thoracic Surgery</i> , 2014 , 46, 602-6	3	1

- 1 Pathophysiology roles and translational opportunities of miRNAs in lung cancer **2022**, 245-253